GMDA On Track, GNFT Soars, HTBX Sparkles, Eli Lilly's Neutralizing Antibody Therapies Get FDA Nod
(2) INDIANAPOLIS (dpa-AFX) - Todays Daily Dose brings you news about KalVistas hereditary angioedema trial results, Heat Biologics encouraging data from its phase II trial of HS-110 in non-small cell lung cancer, Gamidas presentation of full efficacy and safety results of Omidubicel in patients with hematologic malignancies and Neovasc regaining Nasdaq compliance. Read on. 1. Gamidas Presentation At TCT Meetings Catches Eyes Shares of Gamida Cell Ltd. (GMDA) were up over 60% at $16 in extended...
Kalvista Pharma Eli Lilly Neovasc Inc Biotechnology Corporation Kalvista Pharmaceuticals Inc Aeterna Zentaris Inc
Source: finanznachrichten.de